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Objectives: To investigate phenotypic and genotypic patterns of antimicrobial resistance among Gram-
negative bacilli associated with urinary tract infection (UTI) and intra-abdominal infection (IAI) in
medical centres of Jordan and Lebanon.
Methods: Gram-negative bacilli from the SMART study, collected between the years 2011 and 2013,
were ﬁrst identiﬁed at local laboratories. These isolates were shipped to a central laboratory where re-
identiﬁcation, susceptibility testing, and molecular characterization were performed using standard
methods.
Results: Among the 523 UTI-associated isolates, Escherichia coli, Klebsiella pneumoniae, and Proteus
mirabilis were the most frequent (70%, 14%, and 5%, respectively). E. coli, K. pneumoniae, and Pseudomonas
aeruginosa were the most frequent species among the 527 IAI-associated isolates (46%, 14%, and 12%,
respectively). Incidence rates of extended-spectrum beta-lactamase (ESBL) producers among UTI-
associated E. coli, K. pneumoniae, and P. mirabilis were 43%, 54%, and 4%, respectively. Corresponding rates
among IAI-associated isolates were 49%, 56%, and 12%, respectively. Acinetobacter baumannii and P.
aeruginosa isolates showed very disturbing low susceptibility patterns. CTX-M-15 was the most
prevalent ESBL produced. Seventeen isolates were non-susceptible to carbapenems (estimated
prevalence of 1.6%).
Conclusions: The alarmingly high rates of ESBL production and emergence of carbapenemases
emphasize the urgent need to develop antimicrobial stewardship initiatives and to maintain
antimicrobial resistance surveillance systems.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Healthcare-associated infections (HCAIs) continue to cause
signiﬁcant morbidity and mortality among hospitalized patients.1
Gram-negative bacilli, especially in developing countries, are the
most common and the most serious causes of these HCAIs.2 The* Corresponding author. Tel.: +962 2 7200 600x40650; fax: +962 2 7095 777.
E-mail address: wailh@just.edu.jo (W.A. Hayajneh).
http://dx.doi.org/10.1016/j.ijid.2015.04.011
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).burden of these infections is complicated by trends of increasing
antimicrobial resistance, complex clinical infections, and relatively
fewer effective antimicrobials.3 Patterns of antimicrobial resis-
tance in Gram-negative bacilli are increasing alarmingly world-
wide. These patterns include, among others, an increasing
frequency of pathogens producing extended-spectrum beta-
lactamases (ESBLs) and carbapenemases, including Klebsiella
pneumoniae carbapenemases (KPCs). Among these patterns, ESBL
producers continue to be the most common and they usually retain
susceptibility to very few antimicrobials, such as carbapenems.4ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Gram-negative pathogens most frequently associated with UTI and IAI in Jordan
and Lebanon SMART centres between 2011 and 2013
Pathogen UTI IAI
n % % ESBL n % % ESBL
Escherichia coli 367 70 43 242 46 49
Klebsiella pneumoniae 71 14 54 75 14 56
Pseudomonas aeruginosa 17 3 65 12
Proteus mirabilis 26 5 4 41 8 12
Enterobacter cloacae 7 1 29 6
Acinetobacter baumannii 11 2 25 5
Others 24 5 50 9
Total 523 100 527 100
UTI, urinary tract infections; IAI, intra-abdominal infections; SMART, Study for
Monitoring Antimicrobial Resistance Trends; ESBL, extended-spectrum beta-
lactamase.
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dynamic patterns in ESBL producers worldwide, regional and local
studies are equally important to provide evidence-based support
to help develop local antimicrobial stewardship programmes.5
Jordan and Lebanon are Middle Eastern countries with many
common characteristics. They share similar population demo-
graphics and healthcare system characteristics.  Both have
relatively open and liberal social systems, with widely available
multilevel healthcare facilities and pharmaceutical options. It
was therefore felt appropriate to combine data from the two
countries in this report from the Study for Monitoring
Antimicrobial Resistance Trends (SMART). The SMART pro-
gramme generates data on the frequency, antimicrobial suscep-
tibility, and ESBL rates of Gram-negative bacilli associated with
urinary tract infections (UTI) and intra-abdominal infections
(IAI) in participating medical centres in Jordan and Lebanon. It
also highlights the molecular characterization for beta-lactam
resistance.
2. Materials and methods
2.1. Setting and isolate collection
Hospital laboratories from the four participating sites (King
Abdullah University Hospital and Jordan Hospital in Jordan, and
Saint George University Hospital and Rodolphe Me´rieux–Liban
Laboratory in Lebanon) collected non-duplicate consecutive Gram-
negative bacilli from patients with UTI and IAI from 2011 through
2013. The identiﬁcation of isolates was performed according to the
protocol of each participating laboratory. These isolates were then
shipped to a central laboratory (International Health Management
Associates, Inc., Schaumburg, IL, USA) for conﬁrmation of
identiﬁcation and susceptibility testing.
2.2. Susceptibility testing
Antimicrobial susceptibility testing was done at the central
laboratory using custom MicroScan dehydrated broth microdilu-
tion panels (Siemens Medical Solutions Diagnostics, West Sacra-
mento, CA, USA). Minimum inhibitory concentrations (MICs) were
measured and interpreted according to Clinical and Laboratory
Standards Institute (CLSI) guidelines.6,7
Antimicrobial panels included ertapenem (ETP), imipenem
(IPM), cefepime (FEP), ceftazidime (CAZ), ceftazidime–clavulanic
acid, cefoxitin (CFX), ciproﬂoxacin (CIP), amikacin (AMK), levo-
ﬂoxacin (LVX), cefotaxime (CTX), cefotaxime–clavulanic acid,
piperacillin–tazobactam (TZP), ampicillin–sulbactam (SAM), and
ceftriaxone (CRO), with concentrations as described previously.8
Isolates were classiﬁed as ESBL producers if there was at least
an eight-fold reduction in the minimum inhibitory concentration
for ceftazidime or cefotaxime tested in combination with
clavulanic acid versus their MIC values when tested alone.
2.3. Quality control
Quality control testing (QC) was performed using the CLSI
recommended American Type Culture Collection (ATCC) QC
strains, as described previously.
2.4. Molecular characterization and strain typing
ESBLs and carbapenemases were characterized using the
Check-Points microarray (Check-Points B.V., Wageningen,
Netherlands), followed by PCR and sequencing. All Enterobacter-
iaceae that were non-susceptible to ertapenem (using CLSI
breakpoints) were characterized; however, only 50% of the isolatesthat were phenotypically ESBL-positive but ertapenem-suscepti-
ble were characterized due to cost constraints. Therefore,
204 isolates were candidates for molecular characterization.
Three major groups of broad-spectrum beta-lactamases were
distinguished and conﬁrmed using recommended methods:
extended-spectrum beta-lactamases (ESBLs), class C cephalospor-
inases (AmpC), and carbapenemases.
2.5. Statistical analysis
p-Values were calculated with conﬁdence intervals set to 95%.
p-Values of less than 0.05 were considered to indicate statistical
signiﬁcance. Data were analysed using PASW Statistics for
Windows, version 18.0 (SPSS Inc., Chicago, IL, USA).
2.6. Ethical considerations
Appropriate review board approvals were obtained as neces-
sary. All data were kept conﬁdential and patient identifying
information was removed.
3. Results
A total of 1050 pathogens were isolated: 523 UTI-associated
isolates and 527 from IAI. Among all species isolated, Escherichia
coli and Klebsiella pneumoniae were the most frequently identiﬁed.
A detailed description of the numbers and incidence rates of the
species is given in Table 1.
The overall incidence rate of ESBLs among all E. coli, K.
pneumoniae, and Proteus mirabilis isolates combined was 44%.
The highest incidence of ESBL production occurred among IAI-
associated K. pneumoniae isolates (56%), while the lowest was
among UTI-associated P. mirabilis isolates (4%). No statistically
signiﬁcant differences were found between UTI and IAI ESBL
incidences by species. Furthermore, these ESBL incidences did
not increase signiﬁcantly through the three consecutive study
years.
Figures 1 and 2 compare susceptibility rates of ESBL-producing
and non-producing isolates to 10 common antibiotics in both UTI-
and IAI-associated infections. In general, ESBL-producing E. coli
isolates of both infection groups had high susceptibility rates to
imipenem, ertapenem, and amikacin, with no statistically signiﬁ-
cant differences compared to non-ESBL producers. However,
corresponding rates for ESBL-producing K. pneumoniae were
clearly lower. The drop in susceptibility rates among combined
ESBL-producing K. pneumoniae isolates to imipenem (from 100% to
87.5%), ertapenem (from 100% to 87.5%), and amikacin (from 100%
to 92.5%) was statistically signiﬁcant (p = 0.003, 0.003, and 0.023,
respectively).
Figure 1. Antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae (ESBL and non-ESBL producers) associated with UTI in Jordan and Lebanon SMART centres,
2011–2013. (CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; SAM, ampicillin–sulbactam; CIP, ciproﬂoxacin; LVX, levoﬂoxacin; TZP, piperacillin–tazobactam; AMK,
amikacin; ETP, ertapenem; IPM, imipenem).
Figure 2. Antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (ESBL and non-ESBL producers) associated with intra-abdominal
infections in Jordan and Lebanon SMART centres, 2011–2013. (CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; SAM, ampicillin–sulbactam; CIP, ciproﬂoxacin; LVX,
levoﬂoxacin; TZP, piperacillin–tazobactam; AMK, amikacin; ETP, ertapenem; IPM, imipenem).
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Figure 3. Antimicrobial susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii associated with UTI in Jordan and Lebanon SMART centres, 2011–2013. (CIP,
ciproﬂoxacin; LVX, levoﬂoxacin; CAZ, ceftazidime; FEP, cefepime; AMK, amikacin; TZP, piperacillin–tazobactam; IPM, imipenem. The numbers reported on the histogram
refer to the percentage of susceptibility).
W.A. Hayajneh et al. / International Journal of Infectious Diseases 35 (2015) 56–61 59In addition, ESBL producers showed low susceptibility rates to
ﬂuoroquinolones. Moreover, piperacillin–tazobactam had good
activity against ESBL-producing E. coli (91% vs. 87%, p = 0.127), but
had signiﬁcantly diminished activity against ESBL-producing K.
pneumoniae isolates (98% vs. 49%, p < 0.0001). All other tested
antibiotics were mostly ineffective against both ESBL-producing E.
coli and K. pneumoniae isolates.78
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Figure 4. Antimicrobial susceptibility of Pseudomonas aeruginosa and Acinetobacter baum
ciproﬂoxacin; LVX, levoﬂoxacin; CAZ, ceftazidime; FEP, cefepime; AMK, amikacin; TZPFinally, both UTI- and IAI-associated Acinetobacter baumannii
isolates showed very disturbing low susceptibility rates to various
antibiotics (4% to 27%), with imipenem being the most active
antibiotic. Pseudomonas aeruginosa showed better but still
generally very low susceptibility rates (29% to 89%), with
piperacillin–tazobactam being the most active antibiotic
(Figures 3 and 4).88
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annii associated with IAI in Jordan and Lebanon SMART centres, 2011–2013. (CIP,
, piperacillin–tazobactam; IPM, imipenem).
Table 2
Genotypic distribution of various beta-lactamase combinations among 204
Enterobacteriaceae associated with UTI and IAI from Jordan and Lebanon SMART
centres between 2011 and 2013
Organism Molecular summary Number of
isolates
Escherichia coli
(n = 145)
SHV-12; CTX-M-24; OXA-48 1
CTX-M-15; OXA-48 2
CTX-M-15; CMY 7
CTX-M-1; DHA 1
TEM-52; CTX-M-15 1
TEM-33; CTX-M-1 1
TEM-169; CTX-M-27 1
SHV-12; CTX-M-14 1
SHV-12; CTX-M-15 1
SHV-12; KPC-2 1
CTX-M-15 117
CTX-M-14 4
CTX-M-27 3
CTX-M-3 1
CTX-M-55 1
SHV-12 2
Klebsiella pneumoniae
(n = 49)
SHV-12; CTX-M-15; NDM-1; OXA-48 1
SHV-12; CTX-M-15; CMY; OXA-48 1
SHV-12; CTX-M-15; NDM-1 2
SHV-28; CTX-M-15 6
CTX-M-15; NDM-1 4
CTX-M-15; OXA-48 2
CTX-M-15 29
SHV-5 1
CTX-M-8 1
CTX-M-9 1
CTX-M-3 1
Enterobacter cloacae
(n = 4)
ACT-type; OXA-48 1
CTX-M-15; ACT-type 3
Klebsiella oxytoca
(n = 2)
CTX-M-15 1
OXA-48 1
Proteus mirabilis
(n = 2)
CTX-M-15 1
VEB-4 1
Morganella morganii
(n = 1)
SHV-12; DHA; OXA-48 1
Enterobacter asburiae
(n = 1)
MIR-type 1
UTI, urinary tract infections; IAI, intra-abdominal infections; SMART, Study for
Monitoring Antimicrobial Resistance Trends.
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isolates and the ESBL distribution was as follows: (1) TEM-type
beta-lactamases: TEM-169 (n = 1), TEM-33 (n = 1), TEM-52 (n = 1);
(2) CTX-M-type beta-lactamases: CTX-M-15 (n = 178), CTX-M-14
(n = 5), CTX-M-27 (n = 4), CTX-M3 (n = 2), CTX-M-1 (n = 1), CTX-M-
55 (n = 1), CTX-M-9 (n = 1), CTX-M-24 (n = 1); (3) SHV-type beta-
lactamases: SHV-12 (n = 11), SHV-28 (n = 6), SHV-5 (n = 1); (4)
other beta-lactamases: VEB-4 (n = 1). Many of these isolates
produced multiple beta-lactamases (coexistence of two to four
beta-lactamases), as shown in Table 2.
Fifteen isolates (n = 15) produced AmpC, with seven strains of E.
coli and one of K. pneumoniae producing CMY-type AmpC and two
strains of Morganella morganii and one E. coli producing DHA-type
AmpC. Only one strain of Enterobacter cloacae and one of
Enterobacter asburiae produced an ACT- and MIR-type AmpC,
respectively. All these isolates produced other types of beta-
lactamase.
Finally, 17 isolates (1.6%) were non-susceptible to carbape-
nems, with 10 producing OXA-48, seven producing NDM-1, and
one KPC-2. These carbapenemase-producing isolates produced
other beta-lactamases in conjunction.
4. Discussion
Previously published SMART data have shown that the Middle
East has the second highest ESBL prevalence after Asia (around 37%
for either UTI- or IAI-associated infections).8 The current analysis
showed that the combined UTI and IAI-associated ESBL prevalence
was even higher in Jordan and Lebanon (42% and 46%, respective-
ly). The Middle East is the only region in the world where the
prevalence of ESBLs has been increasing signiﬁcantly for both UTI-
and IAI-associated infections,8 which highlights the alarming
patterns of these ﬁndings. These ESBL rates are even higher than
those published in a study from a major tertiary care centre in
Lebanon. That study showed a worrisome and remarkable increase
in ESBL-producing E. coli isolates (4% in 2000 to 30% in 2011) and K.
pneumoniae isolates (12% in 2000 to 28% in 2011).9 A similar
pattern has also been shown speciﬁcally for UTI-associated E. coli
isolates from Lebanese patients, in whom the prevalence of ESBLs
increased consistently from 2.3% in 2000 to 16.8% in 2009.10
Another study from hospitals of north Jordan showed that the
2004 ESBL prevalence among E. coli and K. pneumoniae isolates was
10.8% and 71.4%, respectively.11 An earlier study from the north of
Jordan in 199 detected ESBLs in 34% of K. pneumoniae isolates.12
The high prevalence of ESBLs shown in the present report in
both countries indicates that very limited antimicrobial options
are available to treat infections caused by ESBL-producing E. coli
and K. pneumoniae isolates, with carbapenems and amikacin
remaining the only practical options among those studied in
SMART to treat these infections. However, clinicians are usually
reluctant to use amikacin alone to treat serious infections.
It is very important to emphasize that while carbapenems
maintained excellent activity against ESBL-producing E. coli
isolates during the study period, there was a signiﬁcant drop in
activity against ESBL-producing K. pneumoniae isolates (100% vs.
87.5%). This worrisome observation could be an indication of the
presence of different emerging carbapenemase-encoding genes, as
discussed further below.
While ESBL-producing isolates remained susceptible to imipe-
nem, non-Enterobacteriaceae (A. baumannii and P. aeruginosa)
revealed disappointing susceptibility rates to imipenem (14% and
71%, respectively). This trend presents a great challenge for any
proposed antimicrobial stewardship programme. The rational use
of carbapenems should be maximally practiced to treat individuals
with ESBL-producing pathogens while trying to revive lost activity
against A. baumannii and P. aeruginosa. This is where ertapenem(an antibiotic with A. baumannii and P. aeruginosa sparing activity)
can be appropriately positioned.13
Molecular experiments revealed CTX-M-15 to be the most
prevalent ESBL produced. Unlike most CTX-Ms that preferentially
hydrolyze cefotaxime, CTX-M-15, an Asp-240-Gly variant of CTX-
M-3, increases the catalytic efﬁciency against ceftazidime.14 Our
results are similar to those reported in a previous Lebanese study.15
SHV-12 was the most frequently detected ESBL in the
remaining isolates. In contrast to the present study, among the
SHV-type lactamases, SHV-5 and related enzymes appear to be the
most prevalent ESBLs worldwide and have been responsible for
outbreaks of nosocomial infection in several countries.15–17
Carbapenem-resistant Gram-negative bacilli have been
reported worldwide as a consequence of the acquisition of
carbapenemase genes. Outbreaks caused by carbapenemase genes
have been reported in the Mediterranean region and they are even
considered as endemic in some countries such as in Turkey and
Italy where there is a high prevalence of OXA-48 and VIM-1,
respectively.18,19
The overall prevalence of carbapenem-non-susceptible Enter-
obacteriaceae in Levant (the eastern part of the Mediterranean)
from 2011 to 2013 was 1.6%. These results are in line with
previously reported data in Lebanon that showed a prevalence of
W.A. Hayajneh et al. / International Journal of Infectious Diseases 35 (2015) 56–61 611.2%.20 If compared to the 4.2% reported by the US Centers for
Disease Control and Prevention (CDC) in the year 2011, carbape-
nem resistance in Enterobacteriaceae in Levant appears modest.21
Concerning the distribution of carbapenem resistance among
enterobacterial species, the European network on carbapenemases
reported in 2012 that carbapenemase producers in Europe are
mainly identiﬁed among K. pneumoniae and E. coli.22 The results of
the present study are similar, as 14 out of 17 strains producing
OXA-48 were K. pneumoniae and E. coli.
The carbapenemases reported in the present study were OXA-
48, NDM-1, and KPC-2, the last two being isolated in Jordanian
hospitals only. In Lebanon, different reports have described OXA-
48, IMP-1, and NDM-1 in Enterobacteriaceae and OXA-58 in A.
baumannii.20,23–27 A very recent study28 reported the carbapene-
mase genes blaOXA-23, blaOXA-24, blaGES-11, blaVIM-2, and blaIMP-2 for
the ﬁrst time in Lebanon. To the best of our knowledge, this is the
ﬁrst study reporting the KPC-2 gene in Levant.
In conclusion, this study constitutes the ﬁrst report of SMART
data for the Levant region. It showed ESBL rates to be alarmingly
high and increasing among UTI- and IAI-associated E. coli and K.
pneumoniae infections in both Jordan and Lebanon. While most
ESBL-producing isolates were resistant to the majority of the
antimicrobials evaluated in this study, they remained mostly
susceptible to carbapenems (ertapenem and imipenem) and
amikacin. However, ESBL-producing K. pneumoniae isolates were
less susceptible to carbapenems than ESBL-producing E. coli. This
trend is worrisome and can be explained by the molecular
characterization results. Hence, these data show that even if the
carbapenem-non-susceptible Enterobacteriaceae are moderately
spread in Levant centres, the resistance depends predominantly on
OXA-48 production especially identiﬁed in K. pneumoniae strains.
In addition, antimicrobial options were almost absent for A.
baumannii and were limited for P. aeruginosa isolates.
This study conﬁrms the urgent need to continue surveillance
programmes that monitor trends in antimicrobial activity and
detect new resistance mechanisms as well as the spread of existing
ones, and the need to develop antimicrobial stewardship
initiatives, implement effective infection control programmes,
and measure the effectiveness of such programmes in reducing or
halting the spread of resistance, both regionally and globally.
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